ACTU · Actuate Therapeutics, Inc. · Executive Compensation
$1.07
-0.08 (-6.96%)
At close · Sep 11
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the above matters, we have concluded that there is substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$25.70M
Shares
24.01M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Daniel M. Schmitt | President and Chief Executive Officer | $2,166,522 |
| Andrew P. Mazar | Ph. D. Chief Operating Officer | $1,419,569 |
| Paul Lytle | Chief Financial Officer | $1,006,361 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Daniel M. Schmitt | President and Chief Executive Officer | $5,578,616 |
| Paul Lytle | Chief Financial Officer | $1,896,096 |
| Andrew P. Mazar | Ph. D. Chief Operating Officer | $675,000 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Andrew P. Mazar | Ph. D. Chief Operating Officer | $666,112 |
| Daniel M. Schmitt | President and Chief Executive Officer | $520,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Martin H. Huber, MD | Class III director | Appointed | 2026-05-06 |
| Amy Ronneberg | Director | Appointed | 2024-08-14 |
| Roger Sawhney | Director | Appointed | 2024-08-14 |
| Jason Keyes | Director | Appointed | 2024-08-14 |